FY2025 Earnings Forecast for CervoMed Issued By Roth Capital

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at Roth Capital decreased their FY2025 earnings per share estimates for CervoMed in a note issued to investors on Monday, November 10th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will earn ($2.96) per share for the year, down from their previous estimate of ($2.51). Roth Capital has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q4 2025 earnings at ($0.86) EPS, Q1 2026 earnings at ($0.89) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.66) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.83) EPS.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $1.43 million.

Other analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a report on Wednesday, October 8th. HC Wainwright upgraded shares of CervoMed from a “neutral” rating to a “buy” rating and lifted their price target for the company from $11.00 to $25.00 in a report on Wednesday, November 5th. Chardan Capital reissued a “buy” rating and issued a $15.00 price objective on shares of CervoMed in a research report on Monday, August 11th. Canaccord Genuity Group boosted their price target on shares of CervoMed from $21.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Finally, Zacks Research cut shares of CervoMed from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.86.

CervoMed Stock Performance

CRVO stock traded up $0.13 during mid-day trading on Thursday, hitting $7.54. The company had a trading volume of 7,544 shares, compared to its average volume of 1,508,767. The stock’s fifty day moving average price is $7.99 and its two-hundred day moving average price is $8.18. The firm has a market cap of $69.72 million, a PE ratio of -2.89 and a beta of -0.89. CervoMed has a 12 month low of $1.80 and a 12 month high of $16.94.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CRVO. Bank of New York Mellon Corp bought a new position in CervoMed in the first quarter worth $110,000. Avantax Advisory Services Inc. bought a new stake in shares of CervoMed during the 1st quarter worth approximately $238,000. Citizens Financial Group Inc. RI acquired a new position in shares of CervoMed in the first quarter valued at $244,000. Nuveen LLC acquired a new position in shares of CervoMed during the 1st quarter worth approximately $312,000. Finally, HighTower Advisors LLC acquired a new stake in shares of CervoMed in the 1st quarter valued at $104,000. Institutional investors own 25.15% of the company’s stock.

Insider Buying and Selling at CervoMed

In related news, CEO John J. Alam purchased 5,553 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was acquired at an average price of $7.35 per share, for a total transaction of $40,814.55. Following the completion of the purchase, the chief executive officer owned 1,467,131 shares in the company, valued at approximately $10,783,412.85. This represents a 0.38% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO William Robert Elder purchased 3,500 shares of the stock in a transaction dated Wednesday, November 12th. The shares were purchased at an average price of $7.44 per share, with a total value of $26,040.00. Following the transaction, the chief financial officer directly owned 9,000 shares of the company’s stock, valued at approximately $66,960. The trade was a 63.64% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 35.40% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.